Zobrazeno 1 - 10
of 13
pro vyhledávání: '"D. A. Nicoll‐Griffith"'
Autor:
L. Weiler, D. A. Nicoll‐Griffith
Publikováno v:
ChemInform. 22
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c4037b131536eec771b35d479fe85c11
https://doi.org/10.1002/chin.199128239
https://doi.org/10.1002/chin.199128239
Autor:
N, Chauret, B, Dobbs, R L, Lackman, K, Bateman, D A, Nicoll-Griffith, D M, Stresser, J M, Ackermann, S D, Turner, V P, Miller, C L, Crespi
Publikováno v:
Drug metabolism and disposition: the biological fate of chemicals. 29(9)
Recently, a novel nonfluorescent probe 3-[2-(N,N-diethyl-N-methylammonium)-ethyl]-7-methoxy-4-methylcoumarin (AMMC), which produces a fluorescent metabolite AMHC (3-[2-(N,N-diethyl-N-methylammonium)ethyl]-7-hydroxy-4-methylcoumarin) was used with mic
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::774704df99b987261dcdbadd6bd67104
https://pubmed.ncbi.nlm.nih.gov/11502727
https://pubmed.ncbi.nlm.nih.gov/11502727
In vitro metabolism of the COX-2 inhibitor DFU, including a novel glutathione adduct rearomatization
Autor:
J A, Yergey, L A, Trimble, J, Silva, N, Chauret, C, Li, M, Therien, E, Grimm, D A, Nicoll-Griffith
Publikováno v:
Drug metabolism and disposition: the biological fate of chemicals. 29(5)
The metabolic profile of DFU [5,5-dimethyl-3-(3-fluorophenyl)-4-(4-methylsulphonyl)phenyl-2(5H)-furanone], a potent and selective COX-2 inhibitor, was characterized using in vitro microsomal and hepatocyte incubations. A single product, corresponding
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::8ae02be5946192129642e9eb96f499a7
https://pubmed.ncbi.nlm.nih.gov/11302928
https://pubmed.ncbi.nlm.nih.gov/11302928
Autor:
C, Li, N, Chauret, L A, Trimble, D A, Nicoll-Griffith, J M, Silva, D, MacDonald, H, Perrier, J A, Yergey, T, Parton, R P, Alexander, G J, Warrellow
Publikováno v:
Drug metabolism and disposition: the biological fate of chemicals. 29(3)
CDP-840 is a selective and potent phosphodiesterase type IV inhibitor, whose in vitro metabolism profile was first investigated using liver microsomes from different species. At least 10 phase I oxidative metabolites (M1-M10) were detected in the mic
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::458706185182beeba237821b1ff18b78
https://pubmed.ncbi.nlm.nih.gov/11181489
https://pubmed.ncbi.nlm.nih.gov/11181489
Autor:
D A, Nicoll-Griffith, J M, Silva, N, Chauret, S, Day, Y, Leblanc, P, Roy, J A, Yergey, R, Dixit, D, Patrick
Publikováno v:
Drug metabolism and disposition: the biological fate of chemicals. 29(2)
The drug candidate DFP [5,5-dimethyl-3-(2-isopropoxy)-4-(4-methanesulfonylphenyl)-2(5H)-furanone] is a selective cyclooxygenase-2 inhibitor under evaluation for analgesic and anti-inflammatory therapy. The in vitro metabolic pathways (rat microsomes)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::a99b6f7881f73e5c08abc47b1d1b8acf
https://pubmed.ncbi.nlm.nih.gov/11159806
https://pubmed.ncbi.nlm.nih.gov/11159806
Autor:
D A, Nicoll-Griffith, J P, Falgueyret, J M, Silva, P E, Morin, L, Trimble, C C, Chan, S, Clas, S, Leger, Z, Wang, J A, Yergey, D, Riendeau
Publikováno v:
Drug metabolism and disposition: the biological fate of chemicals. 27(3)
The lactol derivative of a lactone cyclooxygenase-2 inhibitor (DFU) was evaluated in vivo and in vitro for its potential suitability as a prodrug. DFU-lactol was found to be 10 to 20 times more soluble than DFU in a variety of aqueous vehicles. After
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::9f8f2783de323674c3a280cc2620afa1
https://pubmed.ncbi.nlm.nih.gov/10064573
https://pubmed.ncbi.nlm.nih.gov/10064573
Autor:
J M, Silva, P E, Morin, S H, Day, B P, Kennedy, P, Payette, T, Rushmore, J A, Yergey, D A, Nicoll-Griffith
Publikováno v:
Drug metabolism and disposition: the biological fate of chemicals. 26(5)
Induction of cytochromes P450 (P450s) by drugs can lead to drug-drug interactions. Primary hepatocytes have been reported to retain inducible P450s. To optimize the use of primary hepatocytes for predicting induction of P450 (CYP 3A and 2B) expressio
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::91863dd662ec9e400eec13952c554ad8
https://pubmed.ncbi.nlm.nih.gov/9571231
https://pubmed.ncbi.nlm.nih.gov/9571231
Publikováno v:
Drug metabolism and disposition: the biological fate of chemicals. 26(1)
In this study, we report the effect of methanol, dimethyl sulfoxide (DMSO), and acetonitrile on the cytochrome P450 (P450)-mediated metabolism of several substrates in human liver microsomes: phenacetin O-deethylation for P4501A2, coumarin 7-hydroxyl
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::8ffb83b3828195c777c148a28cfd7c40
https://pubmed.ncbi.nlm.nih.gov/9443844
https://pubmed.ncbi.nlm.nih.gov/9443844
Publikováno v:
Drug metabolism and disposition: the biological fate of chemicals. 25(10)
As domestic animals such as cat, horse, and dog increasingly become the clinical targets for drug discovery programs, the need to understand how these animals metabolize xenobiotics becomes more important. In the present study, substrates and inhibit
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::255405122627bf96076b9f7c200eed59
https://pubmed.ncbi.nlm.nih.gov/9321515
https://pubmed.ncbi.nlm.nih.gov/9321515
Publikováno v:
Drug metabolism and disposition: the biological fate of chemicals. 23(10)
Verlukast (MK-0679) is a potent leukotriene D4 antagonist that was under development for the treatment of bronchial asthma. A previously uncharacterized metabolite of verlukast was formed in incubations using rat liver cytosol fortified with glutathi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::c55df3e900f1b0adbd1bde6c8a3a777f
https://pubmed.ncbi.nlm.nih.gov/8654196
https://pubmed.ncbi.nlm.nih.gov/8654196